[Federal Register Volume 59, Number 53 (Friday, March 18, 1994)]
[Unknown Section]
[Page 0]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-6289]


[[Page Unknown]]

[Federal Register: March 18, 1994]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
[Docket No. 94N-0085]

 

Drug Export; Teldafen and Triludan 
(terfenadine and pseudoephedrine hydrochloride) 60 Milligrams/120 
Milligrams Extended Release Tablets

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA) is announcing that 
Marion Merrell Dow, Inc., has filed an application requesting approval 
for the export of the human drug Teldafen and 
Triludan (terfenadine and pseudoephedrine hydrochloride) 60 
milligrams (mg)/120 mg Extended Release Tablets to Belgium and the 
United Kingdom, respectively.

ADDRESSES: Relevant information on this application may be directed to 
the Dockets Management Branch (HFA-305), Food and Drug Administration, 
rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact 
person identified below. Any future inquiries concerning the export of 
human drugs under the Drug Export Amendments Act of 1986 should also be 
directed to the contact person.

FOR FURTHER INFORMATION CONTACT: James E. Hamilton, Division of Drug 
Labeling Compliance (HFD-313), Center for Drug Evaluation and Research, 
Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 
301-594-2073.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of 
the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) 
provide that FDA may approve applications for the export of drugs that 
are not currently approved in the United States. Section 802(b)(3)(B) 
of the act sets forth the requirements that must be met in an 
application for approval. Section 802(b)(3)(C) of the act requires that 
the agency review the application within 30 days of its filing to 
determine whether the requirements of section 802(b)(3)(B) have been 
satisfied. Section 802(b)(3)(A) of the act requires that the agency 
publish a notice in the Federal Register within 10 days of the filing 
of an application for export to facilitate public participation in its 
review of the application. To meet this requirement, the agency is 
providing notice that Marion Merrell Dow, Inc., Marion Park Dr., Kansas 
City, MO 64134-0067, has filed an application requesting approval for 
the export of the human drug Teldafen and Triludan (terfenadine and 
pseudoephedrine hydrochloride) 60mg/ 120 mg Extended Release Tablets to 
Belgium and the United Kingdom. Indications are for the relief of 
symptoms associated with seasonal allergic rhinitis, such as sneezing, 
rhinorrhea, puritus, lacrimation, and nasal congestion. The application 
was received and filed in the Center for Drug Evaluation and Research 
on October 21, 1993, which shall be considered the filing date for 
purposes of the act.
    Interested persons may submit relevant information on the 
application to the Dockets Management Branch (address above) in two 
copies (except that individuals may submit single copies) and 
identified with the docket number found in brackets in the heading of 
this document. These submissions may be seen in the Dockets Management 
Branch between 9 a.m. and 4 p.m., Monday through Friday.
    The agency encourages any person who submits relevant information 
on the application to do so by March 28, 1994, and to provide an 
additional copy of the submission directly to the contact person 
identified above, to facilitate consideration of the information during 
the 30-day review period.
    This notice is issued under the Federal Food, Drug, and Cosmetic 
Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the 
Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the 
Center for Drug Evaluation and Research (21 CFR 5.44).

    Dated: March 8, 1994.
 Raymond E. Hamilton,
 Acting Director, Office of Compliance, Center for Drug Evaluation and 
Research.
[FR Doc. 94-6289 Filed 3-17-94; 8:45 am]
BILLING CODE 4160-01-F